To in-license, or not to in-license?
Our client wanted to evaluate the price potential of a promising new product. The indication had a high unmet need and there was potential for the product to be used in future combination therapies. A lack of analogues and tight timelines added further complexity to the project. Inpharmation’s combination of techniques meant that our client was able to make an informed decision.
Back to Case Studies
A promising opportunity for a new product, in an indication with high unmet need
A top-10 pharma company wanted to evaluate the commercial potential of an in-licensing opportunity. The product was for a rare oncology indication with limited approved therapies. A high level of unmet need, combined with impressive clinical data, presented a great commercial opportunity.
But a lack of analogues, with limited time and budget, made it difficult to identify an optimal pricing strategy
Our client needed an accurate price evaluation to feed into their commercial decision and aid their negotiation strategy. Often, to evaluate the price potential of in-licensing opportunities, analogues are used. However in this instance, with limited approved treatments, using analogues was not an option.
Our client had challenging timelines and there was the potential for the product to be used as a mono and/or combination therapy. This added further complexity to the project.
A potential solution was to use payer interviews only… which came with its own challenges.